NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.

  • By agreement with the publisher, this book is accessible by the search feature, but cannot be browsed.
Cover of Holland-Frei Cancer Medicine

Holland-Frei Cancer Medicine. 6th edition.

Show details

Chapter 45References

, MD and , MD, PhD.

O'shaughnessy JA, Kelloff GJ, Gordon GB. et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002;8:314–346. [PubMed: 11839647]
Alberts DS. A unifying vision of cancer therapy for the 21st century. J Clin Oncol. 1999;17(11 Suppl):13–21. [PubMed: 10630256]
Adair FE, Bogg HJ. Experimental and clinical studies on the treatment of cancer by dichloroethylsulfide (mustard gas) Ann Surg. 1931;93:190–9. [PMC free article: PMC1398743] [PubMed: 17866462]
Goodman LS, Wintrobe MM, Dameshek W. et al. Use of methyl-bis (beta-chlorethyl)amine hydrocholoride and tris (beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA. 1946;132:126–32. [PubMed: 20997191]
Rhoads CP. Nitrogen mustards in treatment of neoplastic disease. JAMA. 1946;131:656–8. [PubMed: 20984885]
Farber S, Diamond LK, Mercer RD. et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroyl-glutamic acid (aminopterin) N Engl J Med. 1948;238:787–93. [PubMed: 18860765]
Rakieten N, Rakieten ML, Nadkani MV. Studies of the diabetogenic action of streptozotocin (NSC-37917) Cancer Chemother Rep. 1963;29:91–8. [PubMed: 13990586]
Murray-Lyon IM, Eddleston AL, Williams R. et al. Treatment of multiple hormone producing islet cell tumour with streptozocin. Lancet. 1968;2:895–8. [PubMed: 4176152]
Schaeppi U, Heyman IA, Fleishman RW. et al. Cis-dichloro-diammineplatinum (II) (NSC-119875) Toxicol Appl Pharmacol. 1973;25:230–41. [PubMed: 4197634]
Higby DJ, Wallace HJ Jr, Albert D, Holland JF. Diamminodichloroplatinum in the chemotherapy of testicular tumors. J Urol. 1974;112:100–4. [PubMed: 4858106]
Wiltshaw E, Kroner T. Phase II study of cis-dichylorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma. Cancer Treat Rep. 1976;60:55–60. [PubMed: 1000519]
Rotman RJ, Cantarow A, Paschkis KE. Studies in 2-acetylaminofluorene carcinogenesis. III. the utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res. 1954;14:119–23. [PubMed: 13126946]
Heidelberger C. On the rational development of a new drug: the example of the fluorinated pyrimidines. Cancer Treat Rep. 1981;65 Suppl 3:3–9. [PubMed: 7346154]
McGinn C, Zalupski M, Shureiqi I. et al. Final report of a Phase I trial of radiation (RT) dose escalation with concurrent weekly FUll dose gemcitabine (GEM) in advanced pancreatic cancer [abstract] Proc Am Soc Clin Oncol. 2001;20:153a.
Elion GB, Hitchings GH, Vander-werff H. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem. 1951;192:505–18. [PubMed: 14907641]
Driscoll JS. The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep. 1984;68:63–76. [PubMed: 6692438]
Boyd MR. Status of the NCI preclinical antitumor drug discovery screen. Princ Pract Oncol Updates. 1989;3:1.
Staquet MJ, Byar DP, Green SB, Rozencweig M. Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep. 1983;67:753–65. [PubMed: 6883351]
Johnson JI, Decker S, Zcharevitz D. et al. Relationship between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424–431. [PMC free article: PMC2363645] [PubMed: 11355958]
Skelham P, Storeng R, Scudiero D. et al. New colorimetric cytotoxicity dosing for anticancer drug screening. J Natl Cancer Inst. 1990;82:1107–12. [PubMed: 2359136]
Chabner BA. In defense of cell-line screening. J Natl Cancer Inst. 1990;82:1083–5. [PubMed: 2359129]
Greever MR, Scheparz S, Chabner BA. The National Cancer Institute: cancer drug discovery and development. Semin Oncol. 1992;19:622–38. [PubMed: 1462164]
Hodes L. Computer-aided selection of compounds for antitumor screening: validation of a statistical-heuristic method. J Chem Inf Comput Sci. 1981;21:128–32. [PubMed: 7287833]
Double JA, Bibby MC. Therapeutic index: a vital component in selection of anticancer agents for clinical trial. J Natl Cancer Inst. 1989;81:988–94. [PubMed: 2659805]
Paull KD, Shoemaker RH, Hodes L. et al. Display and analyses of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithms. J Natl Cancer Inst. 1989;81:1088–92. [PubMed: 2738938]
Weinstein JN, Myuers TG, O'Connor PM. et al. An information-intensive approach to the molecular pharmacology of cancer. Science. 1997;275:343–9. [PubMed: 8994024]
Taverna P, Liu L, Hanson AJ. et al. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol. 2000;46:507–16. [PubMed: 11138465]
O'Connor PM, Jackman J, Bae I. et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57:4285–30. [PubMed: 9331090]
Scherf U, Ross DT, Waltham M. et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet. 2000;24:236–44. [PubMed: 10700175]
Shoemaker RH, Wolpert-Defillipes MK, Kern DH. et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res. 1985;45:2145–53. [PubMed: 3986767]
Hanauske AR, Degen D, Marshall MH. et al. Activation of 2′,2′-difluorodeoxycytidine (gemcitabine) against human tumor colony forming units. Anticancer Drugs. 1992;3:143–6. [PubMed: 1525392]
Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 1992;3:121–4. [PubMed: 1356030]
Bogden AE, Cobb WR, LePage DJ. The 6-day subrenal capsule assay (SRCA): its criticism, biology and review of assay/clinical correlations [review] Prog Clin Biol Res. 1988;276:139–204. [PubMed: 3051020]
Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science. 1960;132:1497.
Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by Quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3. [PubMed: 4126434]
Daley CQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824–30. [PubMed: 2406902]
Witte O. The role of BCR-ABL oncogene in human leukemia. Fifteenth Richard and Hinds Rosenthal Foundation Award Lecture. Cancer Res. 1993;53:485–9. [PubMed: 8425181]
Druker BJ, Tamura S, Buchdunger E. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–66. [PubMed: 8616716]
Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90:3691–8. [PubMed: 9345054]
le Coutre P, Mologni L, Cleris L. et al. In vivo eradication of human BCR-ABL positive leukemia cells with a ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163–8. [PubMed: 9923858]
Druker BJ, Sawyers CL, Talpaz M. et al. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148 in interferon refractory chronic myelogenous leukemia patients [abstract] Proc Annu Meet Am Soc Clin Oncol. 1999;18:7a.
Braziel RM, Launder TM, Druker BJ. et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood. 2002;100:435–41. [PubMed: 12091333]
Demetri G, Von Mehren M, Blanke CD. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80. [PubMed: 12181401]
Van Cutsem E, Karasek P, Oettle H. et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC) [abstract] Proc Annu Meet Am Soc Clin Oncol. 2002;21:130a.
Johnston SRD, Hickish T, Houston S. et al. Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer [abstract] Proc Annu Meet Am Soc Clin Oncol. 2002;21:35a.
Raponi M, Belly R, Atkins D. et al. Pharmacogenomic analysis reveals signaling pathways modulated by R115777 (Zarnestra) in acute myeloid leukemia [abstract] Proc Annu Meet Am Soc Clin Oncol. 2002;21:265a.
Grunwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer. 2002;26:109–64. [PubMed: 12085086]
Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7. [PMC free article: PMC382593] [PubMed: 10619854]
Toledo LM, Lydon NB, Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors [review] Curr Med Chem. 1999;6:775–805. [PubMed: 10495352]
Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest. 2000;105:9–13. [PMC free article: PMC382594] [PubMed: 10619855]
Hanahan D, Weinberg RA. Review: the hallmarks of cancer. Cell. 2000;100:57–70. [PubMed: 10647931]
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–64. [PubMed: 8756718]
Kaelin WG. Choosing anticancer drug targets in the postgenomic era. J Clin Invest. 1999;104:1503–6. [PMC free article: PMC409873] [PubMed: 10587513]
Johnson RK. Screening methods in antineoplastic drug discovery. J Natl Cancer Inst. 1990;82:1082–3. [PubMed: 2193165]
Suftness M, Newman DJ, Snyder K. Discovery and development of antineoplastic agents from natural sources. Bioorgan Marine Chem. 1989;3:131.
Kauvar LM, Villar HO, Sportsman JR. et al. Protein affinity map of chemical space. J Chromatogr B Biomed Sci Appl. 1998;715:93. [PubMed: 9792501]
Kauvar LM, Higgins DL, Villar HO. et al. Predicting ligand binding to proteins by affinity fingerprinting. Chem Biol. 1995;2:107–18. [PubMed: 9383411]
Davignon JP, Craddock JC. The formulation of anticancer drugs. In: Helman K, Carter SK, editors. Fundamentals of cancer chemotherapy. New York: McGraw-Hill; 1987. p. 212-26.
Wiernik PH, Schwartz EL, Strauman JJ. et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987;47:2486–93. [PubMed: 2882837]
Cartwright TH, Cohn A, Varkey JA. et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol. 2002;20:160–4. [PubMed: 11773165]
Adjei AA, Daivd JN, Erlichman C. Farnesyl-transferase inhibitor: use of surrogate markers. Proc AACR-NCI-EORTC Int Conf. 1999;1:145.
Patnaik A, Eckhardt S, Itzbicka E, et al. A Phase I and pharmacokinetic (Pk) study of the farnesyltransferase inhibitor, R115777 in combination with gemcitabine (Gem) [abstract]. Proc Annu Meet Am Soc Clin Oncol 2000;19. Abstract: 5A.
Hidalgo M, Siu LL, Nemunaitis J. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267–79. [PubMed: 11432895]
Campbell KJ, Hersh EM, Stopeck A. et al. A phase I trial of ABI-007 administered weekly for three doses every four weeks in patients with advanced non-hematologic malignancies [abstract] Proc Annu Meet Am Soc Clin Oncol. 2002;21:101a.
Von Hoff DD, Soares N, Gormley P, Poplack DG. Pharmacokinetics of ICRF-187 in the cerebrospinal fluid of subhuman primates. Cancer Treat Rep. 1980;64:734–6. [PubMed: 6775806]
Collins JM, Grieshaber C, Chabner BA. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst. 1990;82:1321–6. [PubMed: 2143234]
Scheithauer W, Clark GM, Salmon SE. et al. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep. 1986;70:1379–82. [PubMed: 3791251]
Davis LE, Alberts DS, Plezia PM. et al. Predictive model for plasma concentration versus time profiles of investigational anticancer drugs in patients. J Natl Cancer Inst. 1988;80:815–9. [PubMed: 3392741]
DeSouza JV, Leiby JM, Staubus AE. et al. Altered pharmacokinetics of fludarabine phosphate by 2′-deoxycoformcin in the diagnosis and analysis of a rate of fludarabine activation. Proc Am Assoc Can Res. 1985;26:1413.
Rinaldi DA, Burris HA, Dorr FA. et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, utilizing the modified continual reassessment method for dose escalation. J Clin Oncol. 1995;13:2842–50. [PubMed: 7595747]
DeGeorge JJ, Ahn CH, Andrews PA. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol. 1998;41:173–85. [PubMed: 9443633]
Verweij J. Starting dose levels for phase I studies [abstract]. Proc 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, March 12–15, 1996, Amsterdam 1996.
Grieshaber CK, Marsoni S. Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep. 1986;70:65–72. [PubMed: 3943115]
Lowe MC. Large animal toxicological studies of anticancer drugs. In: Hellman V, Cortes S, editors. Fundamentals of cancer chemotherapy. New York: McGraw-Hill; 1987. p. 236-47.
Schein P, Anderson T. The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs. Int J Clin Pharmacol. 1973;8:228–38. [PubMed: 4203921]
Eckhardt SG, Baker SD, Britten CD. et al. Phase I and pharmacokinetic study of Irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol. 2000;18:4086–97. [PubMed: 11118470]
Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;18:684–92. [PubMed: 10653884]
Dent SF, Eisenhauer EA. Phase I trial design: are new methodologies being put into practice? Ann Oncol. 1996;7:561–6. [PubMed: 8879368]
Von Hoff DD, Kuhn JG, Clark GM. Design and conduct of Phase I trials. In: Staquet M, Sylvester R, Buyse M, editors. EORTC. Oxford: Oxford Univ. Press; 1984. p. 210-20.
Genre D, Viens P, Von Hoff DD, Clark GM. Patients who are receiving concomitant medications should not systematically be excluded from Phase I studies. Anticancer Drugs. 1999;10:1–7. [PubMed: 10194541]
Penta JS, Rosner G, Trump DL. Choice of starting dose and escalation for Phase I studies of antitumor agents. Cancer Chemother Pharmacol. 1992;31:247–50. [PubMed: 1464163]
Freireich EJ, Gehan EA, Rall DP. et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–44. [PubMed: 4957125]
Schneiderman MA. Mouse to man: statistical problems in bringing a drug to clinical trial. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistical Probability. Berkeley (CA): University of California; 1967. p. 855.
Rothenberg ML, Kuhn JG, Burris HA. et al. A Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993;11:2194–204. [PubMed: 8229134]
Hansen HH, Selawry OS, Muggia FM, Walker MD. Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) Cancer Res. 1971;31:223–7. [PubMed: 4926242]
Gottlieb JA. Phase I and phase II clinical trials: a critical reappraisal. The pharmacologic basis of cancer chemotherapy. Baltimore: Williams and Wilkins; 1974.
Evans WE. Alternative approaches for Phase I studies of anticancer drugs: a role for therapeutic drug monitoring. Ther Drug Monit. 1993;15:492–7. [PubMed: 8122283]
Erlichman C, Moore M, Kerr IG. et al. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole, CI-937 (DUP937) Cancer Res. 1991;51:6317–22. [PubMed: 1933893]
O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46:33–48. [PubMed: 2350571]
O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics. 1996;52:673–84. [PubMed: 8672707]
Faries D. Practical modifications of the continual reassessment method for Phase I cancer clinical trials. J Biopharm Stat 1994;4:147-64. [PubMed: 7951271]
Simon R, Friedlin B, Rubenstein L. et al. Accelerated titration designs for Phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138–1137. [PubMed: 9262252]
Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993;85:1637–43. [PubMed: 8411243]
Freedman J. The ethical analysis of clinical trials: new lessons for and from cancer research. In: Vanderpool HY, editor. The ethics of research involving human subjects. Facing the 21st century. Frederick (MD): University Publishing Group; 1996. p. 319-38.
Emmanuel EJ. A Phase I trial on the ethics of Phase I trials. J Clin Oncol. 1995;13:1049–51. [PubMed: 7738609]
Freedman B. Cohort-specific consent: an honest approach to Phase I clinical cancer studies. IRB: A Review of Human Subjects Research. 1990;12:5–7. [PubMed: 11651972]
Storer BE. Small-sample confidence sets for the MTD in a Phase I clinical trial. Biometrics. 1993;49:1117–25. [PubMed: 8117905]
Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol. 1998;41:429–36. [PubMed: 9554585]
Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for Phase I studies. Stat Med. 1995;14:1149–61. [PubMed: 7667557]
Mick R, Ratain MJ. Model-guided determination of maximum tolerated dose in Phase I clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993;85:217–23. [PubMed: 8423626]
Walling J, Zervos P, McCarthy S. et al. Dose escalation methodology in Phase I clinical trials: a comparison of the modified continual reassessment method (mCRM) and a traditional method. Experience with the multitargeted antifolate (MTA) [abstract] Proc Am Soc Clin Oncol. 1997;16:209a.
Smith TL, Lee JJ, Kantarjian M. et al. Design and results of Phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol. 1996;14:287–95. [PubMed: 8558210]
Eckhardt SG, Siu LL, Clark G. et al. The continual reassessment method (CRM) for dose escalations in Phase I trials in San Antonio do not result in more rapid study completion [abstract] Proc Annu Meet Am Soc Clin Oncol. 1999;18:163a.
Korn EL, Midthune D, Chen TT. et al. A comparison of two Phase I trial designs. Stat Med. 1994;13:1799–806. [PubMed: 7997713]
Graham MA, Workman P. The impact of pharmacokinetically guided dose escalation strategies in Phase I clinical trials. Ann Oncol. 1992;3:339–47. [PubMed: 1616887]
Daugherty C, Ratain MJ, Minami H. et al. Study of cohort-specific consent and patient control in Phase I cancer trials. J Clin Oncol. 1998;16:2305–12. [PubMed: 9667244]
Bowen KJ, Eckhardt J, Clark G. et al. The impact of patient age on the outcome of phase I trials [abstract] Proc Am Soc Clin Oncol. 1993;12:184.
Von Hoff DD. Response rates, duration of response, and dose response effects in Phase I studies of antineoplastic [editorial] Invest New Drugs. 1991;9:115–22. [PubMed: 1827432]
Estey E, Hoth D, Simon R. et al. Therapeutic response in Phase I trials of antineoplastic agents. Cancer Treat Rep. 1986;70:1105–15. [PubMed: 3527410]
Dent S, Zee B, Dancey J, Hanauske A. et al. Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol. 2001;19:785–91. [PubMed: 11157032]
Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs—Twenty-first Richard and Hinds Rosenthal Foundation Award Lecture. Clin Cancer Res. 1998;4:1079. [PubMed: 9607564]
Korn EL, Simon R. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol. 1993;11:794–801. [PubMed: 8478673]
Sessa C, Cavalli F. Who benefits from phase I studies? Ann Oncol. 1990;1:164–65. [PubMed: 2261361]
Rodenhuis S, van den Heuvel WJ, Annyas AA. Patient motivation and informed consent in a Phase I study of an anticancer agent. Eur J Cancer Clin Oncol. 1984;20:457–62. [PubMed: 6539201]
Willems Y, Sessa C. Informing patients about phase I trials—how should it be done? Acta Oncol. 1989;28:106–7. [PubMed: 2706128]
Daugherty CK, Banik DM, Janish L, Ratain MJ. Quantitative analysis of ethical issues in Phase I trials: a survey interview study of 144 advanced cancer patients. IRB: A Review of Human Subjects Research. 2000;22:6–14. [PubMed: 11697385]
Daugherty CK. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol. 1999;17:1601. [PubMed: 10334550]
Melink TJ, Clark GM, Von Hoff DD. The impact of Phase I clinical trials on the quality of life of patients with cancer. Anticancer Drugs. 1992;3:571–6. [PubMed: 1288727]
Petricoin EF III, Ardekani AM, Hitt BA. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–7. [PubMed: 11867112]

By agreement with the publisher, this book is accessible by the search feature, but cannot be browsed.

Copyright © 2003, BC Decker Inc.
Bookshelf ID: NBK13617


  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...